Advanced

Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative

Rydén, Lisa LU ; Loman, Niklas LU ; Larsson, Christer LU ; Hegardt, Cecilia LU ; Vallon-Christersson, Johan LU ; Malmberg, Martin; Lindman, Henrik; Ehinger, Anna LU ; Saal, Lao H. LU and Borg, Åke LU (2018) In British Journal of Surgery 105(2). p.158-168
Abstract (Swedish)
Background

Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The Sweden Cancerome Analysis Network – Breast (SCAN-B) initiative aims to include all patients with breast cancer for tumour genomic analysis, and to deliver molecular subtype and mutational data back to the treating physician.
Methods

An infrastructure for collection of blood and fresh tumour tissue from all patients newly diagnosed with breast cancer was set up in 2010, initially including seven hospitals within the southern... (More)
Background

Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The Sweden Cancerome Analysis Network – Breast (SCAN-B) initiative aims to include all patients with breast cancer for tumour genomic analysis, and to deliver molecular subtype and mutational data back to the treating physician.
Methods

An infrastructure for collection of blood and fresh tumour tissue from all patients newly diagnosed with breast cancer was set up in 2010, initially including seven hospitals within the southern Sweden regional catchment area, which has 1.8 million inhabitants. Inclusion of patients was implemented into routine clinical care, with collection of tumour tissue at local pathology departments for transport to the central laboratory, where routines for rapid sample processing, RNA sequencing and biomarker reporting were developed.
Results

More than 10 000 patients from nine hospitals have currently consented to inclusion in SCAN-B with high (90 per cent) inclusion rates from both university and secondary hospitals. Tumour samples and successful RNA sequencing are being obtained from more than 70 per cent of patients, showing excellent representation compared with the national quality registry as a truly population-based cohort. Molecular biomarker reports can be delivered to multidisciplinary conferences within 1 week.
Conclusion

Population-based collection of fresh tumour tissue is feasible given a decisive joint effort between academia and collaborative healthcare groups, and with governmental support. An infrastructure for genomic analysis and prompt data output paves the way for novel systemic therapy for patients from all hospitals, irrespective of size and location. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Surgery
volume
105
issue
2
pages
158 - 168
publisher
John Wiley & Sons
external identifiers
  • scopus:85040717869
ISSN
1365-2168
DOI
language
English
LU publication?
yes
id
3f8c69c4-1992-459d-8366-7dfdd1e01875
date added to LUP
2018-02-05 16:37:34
date last changed
2018-05-29 12:26:14
@article{3f8c69c4-1992-459d-8366-7dfdd1e01875,
  abstract     = {Background<br/><br/>Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The Sweden Cancerome Analysis Network – Breast (SCAN-B) initiative aims to include all patients with breast cancer for tumour genomic analysis, and to deliver molecular subtype and mutational data back to the treating physician.<br/>Methods<br/><br/>An infrastructure for collection of blood and fresh tumour tissue from all patients newly diagnosed with breast cancer was set up in 2010, initially including seven hospitals within the southern Sweden regional catchment area, which has 1.8 million inhabitants. Inclusion of patients was implemented into routine clinical care, with collection of tumour tissue at local pathology departments for transport to the central laboratory, where routines for rapid sample processing, RNA sequencing and biomarker reporting were developed.<br/>Results<br/><br/>More than 10 000 patients from nine hospitals have currently consented to inclusion in SCAN-B with high (90 per cent) inclusion rates from both university and secondary hospitals. Tumour samples and successful RNA sequencing are being obtained from more than 70 per cent of patients, showing excellent representation compared with the national quality registry as a truly population-based cohort. Molecular biomarker reports can be delivered to multidisciplinary conferences within 1 week.<br/>Conclusion<br/><br/>Population-based collection of fresh tumour tissue is feasible given a decisive joint effort between academia and collaborative healthcare groups, and with governmental support. An infrastructure for genomic analysis and prompt data output paves the way for novel systemic therapy for patients from all hospitals, irrespective of size and location.},
  author       = {Rydén, Lisa and Loman, Niklas and Larsson, Christer and Hegardt, Cecilia and Vallon-Christersson, Johan and Malmberg, Martin and Lindman, Henrik and Ehinger, Anna and Saal, Lao H. and Borg, Åke},
  issn         = {1365-2168},
  language     = {eng},
  month        = {01},
  number       = {2},
  pages        = {158--168},
  publisher    = {John Wiley & Sons},
  series       = {British Journal of Surgery},
  title        = {Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative},
  url          = {http://dx.doi.org/},
  volume       = {105},
  year         = {2018},
}